United Pharm (033270) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.077x

Based on the latest financial reports, United Pharm (033270) has a cash flow conversion efficiency ratio of 0.077x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩35.58 Billion ≈ $24.12 Million USD) by net assets (₩459.17 Billion ≈ $311.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 033270 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

United Pharm - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how United Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data.

United Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of United Pharm ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Helix Acquisition Corp. II Class A Ordinary Shares NASDAQ:HLXB	-0.002x
SaltX Technology Holding AB ST:SALT-B	-0.078x
Harvatek Corp TW:6168	-0.006x
Barings Participation Investors (the Trust) NYSE:MPV	0.031x
Kginicis Co.Ltd KQ:035600	0.020x
Hawesko Holding AG XETRA:HAW	0.448x
Tifico Fiber Indonesia Tbk JK:TFCO	0.022x
Shangri La Hotels Malaysia Bhd KLSE:5517	0.052x

Annual Cash Flow Conversion Efficiency for United Pharm (2011–2025)

The table below shows the annual cash flow conversion efficiency of United Pharm from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see United Pharm (033270) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩454.63 Billion ≈ $308.10 Million	₩51.14 Billion ≈ $34.65 Million	0.112x	+70.52%
2024-12-31	₩406.21 Billion ≈ $275.28 Million	₩26.79 Billion ≈ $18.16 Million	0.066x	-49.81%
2023-12-31	₩378.68 Billion ≈ $256.63 Million	₩49.77 Billion ≈ $33.73 Million	0.131x	-30.38%
2022-12-31	₩337.86 Billion ≈ $228.96 Million	₩63.78 Billion ≈ $43.22 Million	0.189x	+28.77%
2021-12-31	₩300.71 Billion ≈ $203.79 Million	₩44.09 Billion ≈ $29.88 Million	0.147x	+9.82%
2020-12-31	₩276.89 Billion ≈ $187.65 Million	₩36.96 Billion ≈ $25.05 Million	0.133x	-10.75%
2019-12-31	₩255.10 Billion ≈ $172.88 Million	₩38.15 Billion ≈ $25.86 Million	0.150x	-7.30%
2018-12-31	₩228.48 Billion ≈ $154.84 Million	₩36.86 Billion ≈ $24.98 Million	0.161x	+17.54%
2017-12-31	₩201.68 Billion ≈ $136.68 Million	₩27.68 Billion ≈ $18.76 Million	0.137x	-18.90%
2016-12-31	₩177.39 Billion ≈ $120.21 Million	₩30.02 Billion ≈ $20.34 Million	0.169x	+28.50%
2014-12-31	₩161.83 Billion ≈ $109.67 Million	₩21.31 Billion ≈ $14.44 Million	0.132x	-1.80%
2013-12-31	₩141.44 Billion ≈ $95.85 Million	₩18.97 Billion ≈ $12.85 Million	0.134x	-18.19%
2012-12-31	₩133.48 Billion ≈ $90.46 Million	₩21.88 Billion ≈ $14.83 Million	0.164x	-32.90%
2011-12-31	₩113.04 Billion ≈ $76.61 Million	₩27.62 Billion ≈ $18.72 Million	0.244x	--

About United Pharm

KO:033270 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$182.43 Million

₩269.19 Billion KRW

Market Cap Rank

#17018 Global

#671 in Korea

Share Price

₩18640.00

Change (1 day)

-0.05%

52-Week Range

₩17500.00 - ₩22350.00

All Time High

₩95918.11